Half-year report · Q2
4583.TEDINET S100WIB0
Period2025-01-01 → 2025-06-30
Filed2025-08-12
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥252m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥781m | 2024-01-01 → 2024-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥264m | 2024-01-01 → 2024-06-30 | Standalone | Net sales |
| Operating income | −¥537m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Operating income | −¥581m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Ordinary income | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥563m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥562m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Net income | −¥540m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥564m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Total assets | ¥2.0bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.6bn | at 2024-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥443m | at 2025-06-30 | Standalone | Liabilities |
| Total liabilities | ¥549m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.1bn | at 2024-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2025-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.5bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥673m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥677m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Financing cash flow | ¥85m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥455m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-7.97 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.54 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.21 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 76.9% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.0% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 68,053,800 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 66,969,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,387,000 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥280m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | −¥257m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥269m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥447m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥264m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥264m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥135m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥264m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥264m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | −¥312m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 427
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 251796000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 251796000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 251796000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -395868000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 138866000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -257002000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -279819000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | -536822000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-08-12 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第22期中（自 2025年１月１日 至 2025年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Company name in english cover page | FilingDateInstant | Chiome Bioscience Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 小池 正道 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営企画室長 美女平 在彦 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営企画室長 美女平 在彦 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E26096 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Filer name in english | FilingDateInstant | Chiome Bioscience Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |